Sorafenib is a multiple-target tyrosine kinase inhibitor, which can inhibit RAF-1, B-Raf, and kinase activities in the Ras/Raf/MEK/ERK signaling pathway to inhibit tumor cell proliferation, and prolong the overall median survival of patients with advanced HCC [5]. This evidence concerns the gene RAF1 and hepatocellular carcinoma.